Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vir Biotechnology, Inc. - Common Stock
(NQ:
VIR
)
5.085
-0.325 (-6.01%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 9, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vir Biotechnology, Inc. - Common Stock
< Previous
1
2
3
4
Next >
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study
Today 6:00 EDT
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 07, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025
April 30, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025
April 24, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta
March 13, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
February 26, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference
February 19, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
February 12, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC
January 08, 2025
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 18, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
December 12, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
November 26, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
November 25, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
November 18, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
November 18, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
November 15, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
October 31, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024
October 17, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
October 15, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
October 03, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer
September 10, 2024
From
Vir Biotechnology Inc.
Via
Business Wire
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers
September 09, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
September 04, 2024
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 22, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities
August 01, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
September 04, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers
August 01, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024
July 18, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
June 26, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment
June 05, 2024
From
Vir Biotechnology, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.